Abstracts
NSCLC, metastatic
1295O - Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

https://doi.org/10.1093/annonc/mdx380Get rights and content
Under an Elsevier user license
open archive

Cited by (0)